MCID: EBL001
MIFTS: 52

Ebola Hemorrhagic Fever

Categories: Infectious diseases, Oral diseases, Rare diseases

Aliases & Classifications for Ebola Hemorrhagic Fever

MalaCards integrated aliases for Ebola Hemorrhagic Fever:

Name: Ebola Hemorrhagic Fever 12 60 15 17
Ebola Virus Disease 12 77 54 60 3
Hemorrhagic Fever, Ebola 45 74
Ebola Fever 60
Ehf 60

Characteristics:

Orphanet epidemiological data:

60
ebola hemorrhagic fever
Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 60  
Rare infectious diseases


Summaries for Ebola Hemorrhagic Fever

Disease Ontology : 12 A viral infectious disease that is a hemorrhagic fever, has material basis in Zaire ebolavirus, has material basis in Sudan ebolavirus, has material basis in Cote d'Ivoire ebolavirus, or has material basis in Bundibugyo ebolavirus, which are transmitted by contact with the body fluids of an infected animal or person, transmitted by contaminated fomites, or transmitted by infected medical equipment. The infection has symptom fever, has symptom headache, has symptom joint pain, has symptom muscle aches, has symptom sore throat, has symptom weakness, has symptom diarrhea, has symptom vomiting, has symptom stomach pain, has symptom rash, has symptom red eyes, has symptom hiccups, and has symptom internal and external bleeding.

MalaCards based summary : Ebola Hemorrhagic Fever, also known as ebola virus disease, is related to stomatitis and marburg hemorrhagic fever, and has symptoms including fever and pruritus. An important gene associated with Ebola Hemorrhagic Fever is F5 (Coagulation Factor V), and among its related pathways/superpathways are RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways and Interferon gamma signaling. The drugs Vaccines and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include testes, eye and liver, and related phenotypes are fatigue and recurrent pharyngitis

Wikipedia : 77 Ebola virus disease (EVD), also known as Ebola hemorrhagic fever (EHF) or simply Ebola, is a viral... more...

Related Diseases for Ebola Hemorrhagic Fever

Diseases related to Ebola Hemorrhagic Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Related Disease Score Top Affiliating Genes
1 stomatitis 29.4 BST2 DDX58
2 marburg hemorrhagic fever 11.3
3 leprosy 3 11.1
4 allergic urticaria 11.1
5 neurodermatitis 11.1
6 malaria 10.3
7 endometriosis 10.3
8 migraine with or without aura 1 10.2
9 headache 10.2
10 lassa fever 10.2
11 esterase c 10.1
12 ovarian cancer 10.1
13 cystic fibrosis 10.1
14 gastric cancer 10.1
15 breast cancer 10.1
16 renal oncocytoma 10.1
17 chronic interstitial cystitis 10.1
18 uveitis 10.1
19 cholera 10.1
20 mucormycosis 10.0
21 venezuelan equine encephalitis 10.0
22 encephalitis 10.0
23 ige responsiveness, atopic 10.0
24 ovarian cancer 1 10.0
25 pancreatic ductal adenocarcinoma 10.0
26 oral squamous cell carcinoma 10.0
27 squamous cell carcinoma 10.0
28 adenocarcinoma 10.0
29 lung disease 10.0
30 smith-magenis syndrome 9.9
31 dengue virus 9.9
32 melioidosis 9.9
33 myoclonic-atonic epilepsy 9.9
34 hemophagocytic lymphohistiocytosis 9.9
35 meningoencephalitis 9.9
36 pertussis 9.9
37 rabies 9.9
38 hemopericardium 9.9
39 pericardial effusion 9.9
40 diarrhea 9.9
41 disease of mental health 9.9
42 pneumonia 9.9
43 myocarditis 9.9
44 acute respiratory distress syndrome 9.9
45 cytokine deficiency 9.9
46 disseminated intravascular coagulation 9.9 F5 MB
47 argentine hemorrhagic fever 9.9 DDX58 GP2
48 la crosse encephalitis 9.8 DDX58 IFNB1
49 chikungunya 9.8 BST2 DDX58
50 newcastle disease 9.8 DDX58 IFNB1

Graphical network of the top 20 diseases related to Ebola Hemorrhagic Fever:



Diseases related to Ebola Hemorrhagic Fever

Symptoms & Phenotypes for Ebola Hemorrhagic Fever

Human phenotypes related to Ebola Hemorrhagic Fever:

60 33 (show all 27)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatigue 60 33 hallmark (90%) Very frequent (99-80%) HP:0012378
2 recurrent pharyngitis 60 33 hallmark (90%) Very frequent (99-80%) HP:0100776
3 nausea and vomiting 60 33 frequent (33%) Frequent (79-30%) HP:0002017
4 abdominal pain 60 33 frequent (33%) Frequent (79-30%) HP:0002027
5 myalgia 60 33 frequent (33%) Frequent (79-30%) HP:0003326
6 chemosis 60 33 frequent (33%) Frequent (79-30%) HP:0012375
7 headache 60 33 frequent (33%) Frequent (79-30%) HP:0002315
8 gastrointestinal hemorrhage 60 33 frequent (33%) Frequent (79-30%) HP:0002239
9 chest pain 60 33 frequent (33%) Frequent (79-30%) HP:0100749
10 diarrhea 60 33 frequent (33%) Frequent (79-30%) HP:0002014
11 cough 60 33 frequent (33%) Frequent (79-30%) HP:0012735
12 cardiac arrest 60 33 frequent (33%) Frequent (79-30%) HP:0001695
13 leukopenia 60 33 frequent (33%) Frequent (79-30%) HP:0001882
14 restrictive ventilatory defect 60 33 frequent (33%) Frequent (79-30%) HP:0002091
15 seizures 60 33 occasional (7.5%) Occasional (29-5%) HP:0001250
16 renal insufficiency 60 33 occasional (7.5%) Occasional (29-5%) HP:0000083
17 proteinuria 60 33 occasional (7.5%) Occasional (29-5%) HP:0000093
18 thrombocytopenia 60 33 occasional (7.5%) Occasional (29-5%) HP:0001873
19 coma 60 33 occasional (7.5%) Occasional (29-5%) HP:0001259
20 epistaxis 60 33 occasional (7.5%) Occasional (29-5%) HP:0000421
21 macule 60 33 occasional (7.5%) Occasional (29-5%) HP:0012733
22 skin rash 60 33 occasional (7.5%) Occasional (29-5%) HP:0000988
23 acute hepatic failure 60 33 occasional (7.5%) Occasional (29-5%) HP:0006554
24 gingival bleeding 60 33 occasional (7.5%) Occasional (29-5%) HP:0000225
25 lethargy 60 33 occasional (7.5%) Occasional (29-5%) HP:0001254
26 metrorrhagia 60 33 occasional (7.5%) Occasional (29-5%) HP:0100608
27 abnormal bleeding 60 Occasional (29-5%)

UMLS symptoms related to Ebola Hemorrhagic Fever:


fever, pruritus

Drugs & Therapeutics for Ebola Hemorrhagic Fever

Drugs for Ebola Hemorrhagic Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 54)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4,Phase 2,Phase 3,Phase 1
2 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1
3
Coal tar Approved Phase 2, Phase 3,Phase 1 8007-45-2
4
Loperamide Approved Phase 2, Phase 3 53179-11-6 3955
5 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
6 polysaccharide-K Phase 3,Phase 2,Phase 1
7 Iron-Dextran Complex Phase 3,Phase 2,Phase 1
8 Anti-Bacterial Agents Phase 2, Phase 3,Phase 1
9 Anti-Infective Agents Phase 2, Phase 3,Phase 1
10 Dermatologic Agents Phase 2, Phase 3,Phase 1
11 Keratolytic Agents Phase 2, Phase 3,Phase 1
12
Angiotensin II Approved, Investigational Phase 1, Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198
13
Azithromycin Approved Phase 1, Phase 2 83905-01-5 447043 55185
14
Atorvastatin Approved Phase 1, Phase 2 134523-00-5 60823
15
Irbesartan Approved, Investigational Phase 1, Phase 2 138402-11-6 3749
16
Sunitinib Approved, Investigational Phase 1, Phase 2 557795-19-4, 341031-54-7 5329102
17
Lumefantrine Approved Phase 2 82186-77-4 6437380
18
Artemether Approved Phase 2 71963-77-4 68911 119380
19 Lipid Regulating Agents Phase 1, Phase 2,Phase 2
20 Angiotensin Receptor Antagonists Phase 1, Phase 2
21 Antimetabolites Phase 1, Phase 2,Phase 2
22 Anticholesteremic Agents Phase 1, Phase 2,Phase 2
23 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 1, Phase 2,Phase 2
24 Giapreza Phase 1, Phase 2
25 Antihypertensive Agents Phase 1, Phase 2
26
Erlotinib Hydrochloride Phase 1, Phase 2 183319-69-9 176871
27 Angiogenesis Inhibitors Phase 1, Phase 2
28 Hypolipidemic Agents Phase 1, Phase 2,Phase 2
29 Angiotensin II Type 1 Receptor Blockers Phase 1, Phase 2
30 Angiogenesis Modulating Agents Phase 1, Phase 2
31 Protein Kinase Inhibitors Phase 1, Phase 2
32 Angiotensinogen Phase 1, Phase 2
33 Antiviral Agents Phase 2,Phase 1
34 Artemether, Lumefantrine Drug Combination Phase 2
35 Vitamins Phase 2
36 Antibiotics, Antitubercular Phase 2,Phase 1
37 Antidiarrheals Phase 2
38 Immunoglobulins Phase 1, Phase 2
39 Antibodies Phase 1, Phase 2
40 Anti-Inflammatory Agents Phase 2
41 Protective Agents Phase 1
42 Radiation-Protective Agents Phase 1
43 Adjuvants, Immunologic Phase 1
44 Interferon Inducers Phase 1
45 interferons Phase 1
46 Antibodies, Monoclonal Phase 1
47 Laxatives Phase 1
48 Poly I-C Phase 1
49 Gastrointestinal Agents Phase 1
50 Poly ICLC Phase 1

Interventional clinical trials:

(show top 50) (show all 90)
# Name Status NCT ID Phase Drugs
1 International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi Active, not recruiting NCT03072030 Phase 4
2 Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea Completed NCT02342171 Phase 2, Phase 3
3 STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola) Completed NCT02378753 Phase 2, Phase 3
4 Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine Completed NCT03161366 Phase 3
5 Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012) Completed NCT02503202 Phase 3
6 A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants Completed NCT02543268 Phase 3
7 A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants Completed NCT02543567 Phase 3
8 Investigational Therapeutics for the Treatment of People With Ebola Virus Disease Recruiting NCT03719586 Phase 2, Phase 3 ZMapp;Remdesivir;MAb114;REGN-EB3
9 Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo Active, not recruiting NCT02661464 Phase 3
10 Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo During Implementation of Stages 1 and 2 Active, not recruiting NCT02509494 Phase 3
11 Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola) Withdrawn NCT02307591 Phase 2, Phase 3 Best Supportive Care;Best Supportive Care + Amiodarone
12 Multiple Treatments for Ebola Virus Disease (EVD) Unknown status NCT02380625 Phase 1, Phase 2 Azithromycin;Sunitinib and Erlotinib;Atorvastatin and Irbesartan
13 A Clinical Trial to Evaluate the Recombinant Human Type5 Adenovirus Vector Based Ebola Virus Disease Vaccine Completed NCT02575456 Phase 2
14 A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults Completed NCT02485301 Phase 2 Placebo
15 Efficacy of Favipiravir Against Ebola (JIKI) Completed NCT02329054 Phase 2 Favipiravir
16 Efficacy of Favipiravir Against Severe Ebola Virus Disease Completed NCT02662855 Phase 2 Favipiravir
17 A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children Completed NCT02548078 Phase 2
18 Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults Completed NCT02564523 Phase 2
19 Safety, Tolerability and Immunogenicity Study of 2 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo Completed NCT02598388 Phase 2
20 A Clinical Trial on the Candidate Vaccine cAd3-EBOZ in Healthy Adults in Switzerland Completed NCT02289027 Phase 1, Phase 2
21 A Double-blind Randomized Placebo-controlled Study of Safety and Immunogenicity of GamEvac-Lyo Completed NCT03333538 Phase 1, Phase 2
22 A Study to Assess Safety Tolerability and Immunogenicity of Three Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults Completed NCT02416453 Phase 2
23 VSV-ZEBOV Geneva Vaccine Trial Completed NCT02287480 Phase 1, Phase 2
24 Partnership for Research on Ebola VACcinations Recruiting NCT02876328 Phase 2
25 African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola Recruiting NCT03031912 Phase 2
26 GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen Recruiting NCT02818582 Phase 2 GS-5734
27 Yellow Fever Vaccine on Statin/ Non Statin Subjects Recruiting NCT03116802 Phase 2 Stamaril (live attenuated yellow fever vaccine)
28 Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) Active, not recruiting NCT02344407 Phase 2
29 Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV[Delta]G-ZEBOV-GP) for Pre-Exposure Prophylaxis (PREP) in People at Potential Occupational Risk for Ebola Virus Exposure Enrolling by invitation NCT02788227 Phase 2
30 A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants Not yet recruiting NCT03929757 Phase 2
31 Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection Suspended NCT02363322 Phase 1, Phase 2 B/Current Standard of Care Plus ZMapp
32 Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the Semen Terminated NCT02739477 Phase 2 Favipiravir
33 An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease Withdrawn NCT02271347 Phase 2 CMX001
34 A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya. Unknown status NCT02296983 Phase 1
35 A Phase I Study to Assess Ebola Vaccines cAd3-EBO Z and MVA-EBO Z Unknown status NCT02451891 Phase 1
36 A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults. Completed NCT02326194 Phase 1
37 Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults Completed NCT02718469 Phase 1
38 Evaluating an Ebola and a Marburg Vaccine in Uganda Completed NCT00997607 Phase 1
39 A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo Completed NCT02240875 Phase 1
40 A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization Completed NCT02533791 Phase 1
41 Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda Completed NCT02354404 Phase 1
42 Phase 1 Trial of Ebola Vaccine in Mali Completed NCT02267109 Phase 1
43 Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (rVSVΔG-ZEBOV-GP) Completed NCT02283099 Phase 1
44 Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects Completed NCT02370589 Phase 1
45 Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine Completed NCT02374385 Phase 1
46 A Phase I Trial to Evaluate Ad5-EBOV in Healthy Adult Africans in China. Completed NCT02401373 Phase 1
47 Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002) Completed NCT02280408 Phase 1
48 A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV Completed NCT02495246 Phase 1
49 Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004) Completed NCT02314923 Phase 1
50 Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001) Completed NCT02269423 Phase 1

Search NIH Clinical Center for Ebola Hemorrhagic Fever

Cochrane evidence based reviews: hemorrhagic fever, ebola

Genetic Tests for Ebola Hemorrhagic Fever

Anatomical Context for Ebola Hemorrhagic Fever

MalaCards organs/tissues related to Ebola Hemorrhagic Fever:

42
Testes, Eye, Liver, Kidney, Skin, T Cells, Monocytes

Publications for Ebola Hemorrhagic Fever

Articles related to Ebola Hemorrhagic Fever:

(show top 50) (show all 917)
# Title Authors Year
1
Characterization of the plasma proteome of nonhuman primates during Ebola virus disease or melioidosis: a host response comparison. ( 30774579 )
2019
2
Ebola virus disease-related stigma among survivors declined in Liberia over an 18-month, post-outbreak period: An observational cohort study. ( 30811388 )
2019
3
Pre-transfusion testing for Ebola virus disease patients in serious communicable infectious diseases hospitals in Tokyo: A cross-sectional study. ( 30827859 )
2019
4
Modeling the impact of quarantine during an outbreak of Ebola virus disease. ( 30828672 )
2019
5
Development of a screening eye clinic for Ebola virus disease survivors: Lessons learned and rapid implementation at ELWA Hospital in Monrovia, Liberia 2015. ( 30845141 )
2019
6
The Ebola virus disease outbreak in Tonkolili district, Sierra Leone: a retrospective analysis of the Viral Haemorrhagic Fever surveillance system, July 2014-June 2015. ( 30869055 )
2019
7
Ebola virus disease and palliative care in humanitarian crises. ( 30894269 )
2019
8
Recent advances in the development and evaluation of molecular diagnostics for Ebola virus disease. ( 30916590 )
2019
9
Sexual transmission and the probability of an end of the Ebola virus disease epidemic. ( 30928349 )
2019
10
Revitalization of integrated disease surveillance and response in Sierra Leone post Ebola virus disease outbreak. ( 30940125 )
2019
11
2017 Outbreak of Ebola Virus Disease in Northern Democratic Republic of Congo. ( 30942884 )
2019
12
The Cytokine Response Profile of Ebola Virus Disease in a Large Cohort of Rhesus Macaques Treated With Monoclonal Antibodies. ( 30949520 )
2019
13
Comprehensive Clinical and Laboratory Follow-up of a Female Patient With Ebola Virus Disease: Sierra Leone Ebola Virus Persistence Study. ( 30949523 )
2019
14
Shifting the Paradigm - Applying Universal Standards of Care to Ebola Virus Disease. ( 30970184 )
2019
15
Control of Ebola virus disease outbreaks: Comparison of health care worker-targeted and community vaccination strategies. ( 30981563 )
2019
16
Health care workers' awareness and infection control practices about Ebola virus disease in Hajj 2015. ( 30981653 )
2019
17
Evaluation of Ebola virus disease surveillance system in Tonkolili District, Sierra Leone. ( 30984324 )
2019
18
Medical countermeasures during the 2018 Ebola virus disease outbreak in the North Kivu and Ituri Provinces of the Democratic Republic of the Congo: a rapid genomic assessment. ( 31000464 )
2019
19
2018 Ebola virus disease outbreak in Équateur Province, Democratic Republic of the Congo: a retrospective genomic characterisation. ( 31000465 )
2019
20
Caring for patients with Ebola virus disease: Are U.S. biocontainment centers ready for the next outbreak? ( 31010606 )
2019
21
Ebola Virus Disease: Clinical Challenges, Recognition, and Management. ( 31027659 )
2019
22
Ebola Virus Disease in Women and Children. ( 31033589 )
2019
23
Understanding long-term effects of Ebola virus disease. ( 31036880 )
2019
24
Anti-Ebola therapy for patients with Ebola virus disease: a systematic review. ( 31046707 )
2019
25
Impact of Intravenous Fluid Therapy on Survival Among Patients with Ebola Virus Disease: An International Multisite Retrospective Cohort Study. ( 31050703 )
2019
26
Evaluating the impact of intravenous fluid resuscitation on survival for the management of patients with Ebola Virus Disease. ( 31055594 )
2019
27
Reproductive health sequelae among women who survived Ebola virus disease in Liberia. ( 31074837 )
2019
28
Neurological, Cognitive, and Psychological Findings Among Survivors of Ebola Virus Disease From the 1995 Ebola Outbreak in Kikwit, Democratic Republic of Congo: A Cross-sectional Study. ( 30107392 )
2019
29
Drug Repurposing for Ebola Virus Disease: Principles of Consideration and the Animal Rule. ( 30244014 )
2019
30
Environmental temperature and case fatality of patients with Ebola virus disease in Sierra Leone and Liberia, 2014-2015: a retrospective cohort study. ( 30307686 )
2019
31
Adherence to Universal Travel Screening in the Emergency Department During Epidemic Ebola Virus Disease. ( 30342859 )
2019
32
Stillbirths and neonatal deaths surveillance during the 2014-2015 Ebola virus disease outbreak in Sierra Leone. ( 30467853 )
2019
33
Immune parameters and outcomes during Ebola virus disease. ( 30626757 )
2019
34
Phylodynamic Analysis of Ebola Virus Disease Transmission in Sierra Leone. ( 30654482 )
2019
35
Children's needs in an Ebola virus disease outbreak. ( 30660206 )
2019
36
Macrophage Activation Marker Soluble CD163 Associated with Fatal and Severe Ebola Virus Disease in Humans1. ( 30666927 )
2019
37
Clinical presentation of pregnant women in isolation units for Ebola virus disease in Sierra Leone, 2014. ( 30706470 )
2019
38
Evidence-Based Clinical Management of Ebola Virus Disease and Epidemic Viral Hemorrhagic Fevers. ( 30712765 )
2019
39
The evolution of supportive care for Ebola virus disease. ( 30732851 )
2019
40
Consensus building around nutrition lessons from the 2014-16 Ebola virus disease outbreak in Guinea and Sierra Leone. ( 30753437 )
2019
41
Ebola virus disease. ( 30777297 )
2019
42
Laboratory findings, compassionate use of favipiravir, and outcome in patients with Ebola virus disease, Guinea, 2015 - a retrospective observational study. ( 30788508 )
2019
43
Plasma lipidome reveals critical illness and recovery from human Ebola virus disease. ( 30808769 )
2019
44
Molecular detection of dengue virus in patients suspected of Ebola virus disease in Ghana. ( 30566466 )
2018
45
Immunogenicity of a Candidate Ebola Hemorrhagic Fever Vaccine in Mice Based on Controlled In Vitro Expression of Ebolavirus Glycoprotein. ( 30095362 )
2018
46
Clinical Manifestations and Pathogenesis of Uveitis in Ebola Virus Disease Survivors. ( 29993303 )
2018
47
Experiences of Response Measures against the 4 Suspected Cases of Ebola Virus Disease from West Africa in the National Center for Global Health and Medicine, Tokyo, Japan. ( 29093311 )
2018
48
Ebola virus disease: Report from the task force on tropical diseases by the World Federation of Societies of Intensive and Critical Care Medicine. ( 29128378 )
2018
49
Prognostic and Predictive Factors of Ebola Virus Disease Outcome in Elderly People during the 2014 Outbreak in Guinea. ( 29141743 )
2018
50
Ebola virus disease: an update on post-exposure prophylaxis. ( 29153266 )
2018

Variations for Ebola Hemorrhagic Fever

Expression for Ebola Hemorrhagic Fever

Search GEO for disease gene expression data for Ebola Hemorrhagic Fever.

Pathways for Ebola Hemorrhagic Fever

GO Terms for Ebola Hemorrhagic Fever

Biological processes related to Ebola Hemorrhagic Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 type I interferon signaling pathway GO:0060337 9.4 BST2 IFNB1
2 humoral immune response GO:0006959 9.37 BST2 IFNB1
3 defense response to virus GO:0051607 9.33 BST2 DDX58 IFNB1
4 negative regulation of viral genome replication GO:0045071 9.32 BST2 IFNB1
5 response to exogenous dsRNA GO:0043330 9.26 DDX58 IFNB1
6 cellular response to exogenous dsRNA GO:0071360 8.96 DDX58 IFNB1
7 response to virus GO:0009615 8.8 BST2 DDX58 IFNB1

Sources for Ebola Hemorrhagic Fever

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....